{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T16:15:02Z","timestamp":1790612102218,"version":"4.1.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2024,8,13]],"date-time":"2024-08-13T00:00:00Z","timestamp":1723507200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100005089","name":"Beijing Municipal Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005089","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,10,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Anti-Sj\u00f6gren's syndrome type A (anti-SSA) antibodies are non-organ-specific autoantibodies highly prevalent in various autoimmune diseases. This study primarily investigated the prevalence of anti-SSA antibodies in the health screening population. Additionally, we explored the clinical features of the anti-SSA antibody-positive population and evaluated the development of connective tissue diseases (CTD) over the years in individuals with anti-SSA antibodies for whom follow-up was available. A total of, 64\u2005045 individuals without a history of CTD from 2013 to 2022 who visited Peking Union Medical College Hospital for health screening were screened for autoimmune antibodies: 1.7% (1091\/64\u2005045) of the Chinese health screening population were positive for anti-SSA antibodies, with a prevalence of 0.9% (290\/33\u2005829) in men and 2.7% (801\/30\u2005216) in women. Compared with matched autoantibody-negative controls, anti-SSA antibody-positive individuals had higher levels of serological abnormalities, including erythrocyte sedimentation rate (ESR) [10 (6\u201315) mm\/h vs. 7 (4\u201312) mm\/h, P\u2005&amp;lt;\u20050.0001], rheumatoid factor (RF) [7.15 (4.30\u201316.90) IU\/ml vs. 5.00 (3.20\u20137.90) IU\/ml, P\u2005&amp;lt;\u20050.0001], and immunoglobulin G [13.09 (11.20\u201315.45) g\/L vs. 11.34 (9.85\u201313.18) g\/L, P\u2005&amp;lt;\u20050.0001], and lower levels of white blood cells (WBC; 5.49\u2005\u00b1\u20051.50 \u00d7 109\/L vs. 5.82\u2005\u00b1\u20051.49 \u00d7 109\/L, P\u2005&amp;lt;\u20050.0001). Additionally, they had a higher proportion of coexisting thyroid autoantibodies, including anti-thyroid peroxidase antibodies (TPO-Ab) (17.1% vs. 11.3%, P\u2005&amp;lt;\u20050.0001) and anti-thyroglobulin antibodies (Tg-Ab) (17.8% vs. 11.0%, P\u2005&amp;lt;\u20050.0001). Among the 381 subjects who were anti-SSA positive and followed up for a median of 4.6 years, 146 (38.3%) individuals developed CTD, including 68 (17.8%) cases of primary Sj\u00f6gren\u2019s syndrome (pSS), 10 (2.6%) cases of rheumatoid arthritis (RA), 5 (1.3%) cases of systemic lupus erythematosus (SLE), 4 (1.0%) cases of secondary Sj\u00f6gren\u2019s syndrome (sSS), and 59 (15.5%) cases of undifferentiated connective tissue disease (UCTD). In all, 235 (61.7%) individuals did not develop CTD over a median time of 5.9 (2.9\u20138.1) years after the earliest autoantibody detection. Elevated ESR (&amp;gt;20 mm\/h), RF positivity (&amp;gt;20 IU\/ml), and female gender were identified as independent risk factors for CTD among the anti-SSA antibody-positive individuals. Anti-SSA antibodies were found in 17 among approximately 1000 individuals without a history of autoimmune diseases. Anti-SSA antibody-positive individuals are advised to periodically monitor thyroid function. Elevated ESR (&amp;gt;20 mm\/h), female gender, and RF positivity may delineate a high-risk cohort for CTDs.<\/jats:p>","DOI":"10.1093\/cei\/uxae073","type":"journal-article","created":{"date-parts":[[2024,8,12]],"date-time":"2024-08-12T05:59:14Z","timestamp":1723442354000},"page":"169-176","source":"Crossref","is-referenced-by-count":7,"title":["Prevalence and clinical significance of anti-SSA antibody in the Chinese health screening population"],"prefix":"10.1093","volume":"218","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-7111-3437","authenticated-orcid":false,"given":"Yimeng","family":"Jia","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College , Beijing,","place":["China"]},{"name":"National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), The Ministry of Education Key Laboratory , Beijing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuqi","family":"Luan","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College , Beijing,","place":["China"]},{"name":"National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), The Ministry of Education Key Laboratory , Beijing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sicheng","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College , Beijing,","place":["China"]},{"name":"National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), The Ministry of Education Key Laboratory , Beijing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7808-9867","authenticated-orcid":false,"given":"Wen","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College , Beijing,","place":["China"]},{"name":"National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), The Ministry of Education Key Laboratory , Beijing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mengtao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College , Beijing,","place":["China"]},{"name":"National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), The Ministry of Education Key Laboratory , Beijing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tengda","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Health and Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College , Beijing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunyun","family":"Fei","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College , Beijing,","place":["China"]},{"name":"National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), The Ministry of Education Key Laboratory , Beijing,","place":["China"]},{"name":"Department of Health and Medicine, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College , Beijing,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2024,8,13]]},"reference":[{"key":"2024101617254111200_CIT0001","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1016\/S0140-6736(10)61965-4","article-title":"Primary biliary cirrhosis","volume":"377","author":"Selmi","year":"2011","journal-title":"Lancet"},{"key":"2024101617254111200_CIT0002","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1056\/NEJMoa021933","article-title":"Development of autoantibodies before the clinical onset of systemic lupus erythematosus","volume":"349","author":"Arbuckle","year":"2003","journal-title":"N Engl J Med"},{"key":"2024101617254111200_CIT0003","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.autrev.2010.09.005","article-title":"Clinical and laboratory aspects of Ro\/SSA-52 autoantibodies","volume":"10","author":"Defendenti","year":"2011","journal-title":"Autoimmun Rev"},{"key":"2024101617254111200_CIT0004","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.autrev.2017.02.010","article-title":"Neonatal lupus: follow-up in infants with anti-SSA\/Ro antibodies and review of the literature","volume":"16","author":"Zuppa","year":"2017","journal-title":"Autoimmun Rev"},{"key":"2024101617254111200_CIT0005","doi-asserted-by":"crossref","first-page":"103013","DOI":"10.1016\/j.autrev.2021.103013","article-title":"An updated review of anti-Ro52 (TRIM21) antibodies impact in connective tissue diseases clinical management","volume":"21","author":"Decker","year":"2022","journal-title":"Autoimmun Rev"},{"key":"2024101617254111200_CIT0006","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/j.1478-3231.2011.02502.x","article-title":"Prognostic implications of antibodies to Ro\/SSA and soluble liver antigen in type 1 autoimmune hepatitis","volume":"32","author":"Montano-Loza","year":"2012","journal-title":"Liver Int"},{"key":"2024101617254111200_CIT0007","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1002\/art.39214","article-title":"Prediction of Sj\u00f6gren\u2019s syndrome years before diagnosis and identification of patients with early onset and severe disease course by autoantibody profiling","volume":"67","author":"Theander","year":"2015","journal-title":"Arthritis Rheumatol"},{"key":"2024101617254111200_CIT0008","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1002\/art.39859","article-title":"2016 American College of Rheumatology\/European League Against Rheumatism classification criteria for primary Sj\u00f6gren\u2019s syndrome: a consensus and data-driven methodology involving three international patient cohorts","volume":"69","author":"Shiboski","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2024101617254111200_CIT0009","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1136\/annrheumdis-2018-214819","article-title":"2019 European League Against Rheumatism\/American College of Rheumatology classification criteria for systemic lupus erythematosus","volume":"78","author":"Aringer","year":"2019","journal-title":"Ann Rheum Dis"},{"key":"2024101617254111200_CIT0010","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1136\/ard.2010.138461","article-title":"2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative","volume":"69","author":"Aletaha","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"2024101617254111200_CIT0011","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1172\/JCI112892","article-title":"Implications of anti-Ro\/Sj\u00f6gren\u2019s syndrome A antigen autoantibody in normal sera for autoimmunity","volume":"79","author":"Gaither","year":"1987","journal-title":"J Clin Invest"},{"key":"2024101617254111200_CIT0012","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/0090-1229(85)90045-5","article-title":"Antinuclear, anticytoplasmic, and anti-Sjogren\u2019s syndrome antigen A (SS-A\/Ro) antibodies in female blood donors","volume":"36","author":"Fritzler","year":"1985","journal-title":"Clin Immunol Immunopathol"},{"key":"2024101617254111200_CIT0013","doi-asserted-by":"crossref","first-page":"625896","DOI":"10.3389\/fimmu.2020.625896","article-title":"Anti-TIF-1\u03b3 antibody detection using a commercial kit vs in-house immunoblot: usefulness in clinical practice","volume":"11","author":"Mariscal","year":"2020","journal-title":"Front Immunol"},{"key":"2024101617254111200_CIT0014","doi-asserted-by":"crossref","first-page":"e701","DOI":"10.1212\/NXI.0000000000000701","article-title":"Diagnostic yield of commercial immunodots to diagnose paraneoplastic neurologic syndromes","volume":"7","author":"D\u00e9chelotte","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"2024101617254111200_CIT0015","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1046\/j.1365-2249.2000.01195.x","article-title":"Association of neutropenia in Systemic Lupus Erythematosus (SLE) with anti-Ro and binding of an immunologically cross-reactive neutrophil membrane antigen","volume":"120","author":"Kurien","year":"2000","journal-title":"Clin Exp Immunol"},{"key":"2024101617254111200_CIT0016","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1007\/s00415-002-0781-6","article-title":"Increased lymphocyte death by neglect-apoptosis is associated with Lymphopenia and autoantibodies in lupus patients presenting with neuropsychiatric manifestations","volume":"249","author":"Silva","year":"2002","journal-title":"J Neurol"},{"key":"2024101617254111200_CIT0017","doi-asserted-by":"crossref","first-page":"892","DOI":"10.4049\/jimmunol.136.3.892","article-title":"Specificity analysis of human anti-DNA antibodies","volume":"136","author":"Hoch","year":"1986","journal-title":"J Immunol"},{"key":"2024101617254111200_CIT0018","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/BF00541329","article-title":"IgG antibodies to SS-B (La), RNP\/Sm and DNA are produced by PWM-stimulated normal human lymphocytes in culture","volume":"5","author":"Mumford","year":"1985","journal-title":"Rheumatol Int"},{"key":"2024101617254111200_CIT0019","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1084\/jem.20080611","article-title":"Functional anergy in a subpopulation of naive B cells from healthy humans that express autoreactive immunoglobulin receptors","volume":"206","author":"Duty","year":"2009","journal-title":"J Exp Med"},{"key":"2024101617254111200_CIT0020","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1146\/annurev-immunol-092419-031130","article-title":"Age-associated B cells","volume":"38","author":"Cancro","year":"2020","journal-title":"Annu Rev Immunol"},{"key":"2024101617254111200_CIT0021","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.autrev.2004.03.004","article-title":"Inflamm-aging: autoimmunity, and the immune-risk phenotype","volume":"3","author":"Boren","year":"2004","journal-title":"Autoimmun Rev"},{"key":"2024101617254111200_CIT0022","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1016\/j.jaut.2012.05.011","article-title":"Endocrine alterations in primary Sjogren\u2019s syndrome: an overview","volume":"39","author":"Mavragani","year":"2012","journal-title":"J Autoimmun"},{"key":"2024101617254111200_CIT0023","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/ard.2003.010058","article-title":"Autoimmune thyroiditis and anti-thyroid antibodies in primary Sjogren\u2019s syndrome: a case-control study","volume":"63","author":"Tunc","year":"2004","journal-title":"Ann Rheum Dis"},{"key":"2024101617254111200_CIT0024","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1089\/thy.2007.0398","article-title":"Autoimmune thyroid diseases in a large group of Hungarian patients with primary Sj\u00f6gren\u2019s syndrome","volume":"19","author":"Zeher","year":"2009","journal-title":"Thyroid"},{"key":"2024101617254111200_CIT0025","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.humimm.2006.06.006","article-title":"Clinical, serologic, and genetic profiles of patients with associated Sj\u00f6gren\u2019s syndrome and systemic lupus erythematosus","volume":"67","author":"Szanto","year":"2006","journal-title":"Hum Immunol"},{"key":"2024101617254111200_CIT0026","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1196\/annals.1422.046","article-title":"Sj\u00f6gren\u2019s syndrome--a plethora of clinical and immunological phenotypes with a complex genetic background","volume":"1108","author":"Jonsson","year":"2007","journal-title":"Ann N Y Acad Sci"},{"key":"2024101617254111200_CIT0027","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1007\/s10067-008-0917-x","article-title":"Interstitial lung disease and Sj\u00f6gren\u2019s syndrome in primary biliary cirrhosis: a causal or casual association","volume":"27","author":"Liu","year":"2008","journal-title":"Clin Rheumatol"},{"key":"2024101617254111200_CIT0028","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/hep.1840110504","article-title":"Sj\u00f6gren\u2019s syndrome in patients with primary biliary cirrhosis","volume":"11","author":"Tsianos","year":"1990","journal-title":"Hepatology"},{"key":"2024101617254111200_CIT0029","first-page":"1760","article-title":"Clinical and serological characteristics of anti-Ro\/SS-A and anti-La\/SS-B negative primary Sj\u00f6gren\u2019s syndrome: a comparative study","volume":"28","author":"Bodak\u00e7i","year":"2024","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"2024101617254111200_CIT0030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jaut.2011.11.005","article-title":"Primary biliary cirrhosis and Sj\u00f6gren\u2019s syndrome: autoimmune epithelitis","volume":"39","author":"Selmi","year":"2012","journal-title":"J Autoimmun"},{"key":"2024101617254111200_CIT0031","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s12016-015-8471-1","article-title":"The coexistence of Sj\u00f6gren\u2019s syndrome and primary biliary cirrhosis: a comprehensive review","volume":"48","author":"Sun","year":"2015","journal-title":"Clin Rev Allergy Immunol"},{"key":"2024101617254111200_CIT0032","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1002\/1529-0131(200103)44:3<647::AID-ANR113>3.0.CO;2-I","article-title":"Long-term outcome of mothers of children with isolated heart block in Finland","volume":"44","author":"Julkunen","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2024101617254111200_CIT0033","doi-asserted-by":"crossref","first-page":"3445","DOI":"10.1002\/art.38872","article-title":"Antibody-secreting cell specificity in labial salivary glands reflects the clinical presentation and serology in patients with Sj\u00f6gren\u2019s syndrome","volume":"66","author":"Maier-Moore","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2024101617254111200_CIT0034","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/cei.12058","article-title":"Ro52- and Ro60-specific B cell pattern in the salivary glands of patients with primary Sj\u00f6gren\u2019s syndrome","volume":"172","author":"Aqrawi","year":"2013","journal-title":"Clin Exp Immunol"},{"key":"2024101617254111200_CIT0035","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1136\/annrheumdis-2020-219296","article-title":"Correspondence on \u201cPerformance of the 2019 EULAR\/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities.\u201d","volume":"82","author":"R\u00f6nnelid","year":"2023","journal-title":"Ann Rheum Dis"},{"key":"2024101617254111200_CIT0036","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1136\/annrheumdis-2013-203863","article-title":"International recommendations for the assessment of autoantibodies to cellular antigens referred to as anti-nuclear antibodies","volume":"73","author":"Agmon-Levin","year":"2014","journal-title":"Ann Rheum Dis"},{"key":"2024101617254111200_CIT0037","doi-asserted-by":"crossref","first-page":"e000732","DOI":"10.1136\/lupus-2022-000732","article-title":"Autoantibodies associated with systemic sclerosis in three autoimmune diseases imprinted by type I interferon gene dysregulation: a comparison across SLE, primary Sj\u00f6gren\u2019s syndrome and systemic sclerosis","volume":"9","author":"Andraos","year":"2022","journal-title":"Lupus Sci Med"}],"container-title":["Clinical and Experimental Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/cei\/advance-article-pdf\/doi\/10.1093\/cei\/uxae073\/59018509\/uxae073.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/218\/2\/169\/59812007\/uxae073.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cei\/article-pdf\/218\/2\/169\/59812007\/uxae073.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T17:26:05Z","timestamp":1729099565000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cei\/article\/218\/2\/169\/7732161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,8,13]]},"references-count":37,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2024,8,13]]},"published-print":{"date-parts":[[2024,10,16]]}},"URL":"https:\/\/doi.org\/10.1093\/cei\/uxae073","relation":{},"ISSN":["0009-9104","1365-2249"],"issn-type":[{"value":"0009-9104","type":"print"},{"value":"1365-2249","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,11]]},"published":{"date-parts":[[2024,8,13]]}}}